Volume 17, Number 4—April 2011
Drug-Resistant Pandemic (H1N1) 2009, South Korea1
|Median age, y (range)||5 (1–63)|
|No. at high risk for influenza-related complications|
|<59 mo of age||6|
|Chronic medical disorders||9|
|Metabolic, including diabetes†||2|
|Pulmonary, including asthma||1|
|Cardiovascular, excluding hypertension||0|
|Median days from symptom onset to viral isolation (range)||2 (0–9)|
|Median days from symptom onset to development of resistance
|Hospitalization duration, d, median (range)||15 (6–53)|
|Symptom duration, d, median (range)
|No. with respiratory illness related to influenza||11|
|Secondary bacterial pneumonia||2|
| Secondary bacterial pneumonia and acute respiratory distress syndrome
|Reasons for requesting drug-resistance testing|
| Prolonged viral shedding
|No. with co-infections§
*Specimens were obtained from oropharyngeal (n = 7) and nasopharyngeal (n = 2) swabs, nasopharyngeal washings (n = 1), and brochoalveolar lavage fluid (n = 1).
†One patient had diabetes and chronic renal failure.
‡Patients who had underlying diseases such as HIV infection, malignancy, liver cirrhosis, or chronic renal failure, or patients receiving immunosuppressive treatment.
§Carbapenem-resistant Pseudomonas aeruginosa (patient 3), carbapenem-resistant Acinetobacter baumanii (patient 4), and penicillin-susceptible Streptococcus pneumonia (patient 10).
¶Of the 3 patients, 1 was infected with carbapenem-resistant P. aeruginosa (patient 3) and 1 was infected with carbapenem-resistant A. baumanii (patient 4).
1Presented in part at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12–15; Boston, Massachusetts, USA (late-breaker posters session, abstract V-448c).